Literature DB >> 8023551

Adverse reactions after diphtheria-tetanus booster in 10-year-old schoolchildren in relation to the type of vaccine given for the primary vaccination.

M Blennow1, M Granström, A Strandell.   

Abstract

This prospective open study investigated adverse reactions in 527 schoolchildren to a diphtheria-tetanus (DT) booster given within a national vaccination programme at 10 years of age. Evaluation was based on those whose immunization records showed that they had received either three doses of an adsorbed DT vaccine (n = 388) or a non-adsorbed DT-pertussis vaccine (DTP) (n = 69) for primary series vaccination. No differences in systemic reactions to the booster between the two groups were observed. Local reactions were significantly (p < 0.001) more common 1 day after vaccination in children who had received DT for primary series vaccination: redness, 73% compared with 23%; swelling, 56% versus 15%; and itching, 47% versus 21%. One and 2 weeks after the booster, itching was still more pronounced in the group who had received DT for primary series vaccination (p < 0.001 and 0.014, respectively). The study indicates that there was a real basis for the increase in spontaneous notifications of local side-effects to the school DT booster in Sweden. The most likely cause for the increase seems to be the aluminium adjuvant in the vaccine given for primary vaccination, a late and unexpected consequence of a change in the infant immunization programme.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8023551     DOI: 10.1016/0264-410x(94)90119-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  1 in total

1.  Evaluation of immunogenicity and safety of the new tetanus-reduced diphtheria (Td) vaccines (GC1107) in healthy Korean adolescents: a phase II, double-blind, randomized, multicenter clinical trial.

Authors:  Jung-Woo Rhim; Kyung-Yil Lee; Sang-Yong Kim; Jong-Hyun Kim; Hyun-Hee Kim; Hwang Min Kim; Young-Youn Choi; Sang-Hyuk Ma; Dong-Ho Kim; Dong Ho Ahn; Jin-Han Kang
Journal:  J Korean Med Sci       Date:  2013-03-27       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.